The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood. 19 mai, vol.127, issue.20, pp.2375-90, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment, Blood. 15 juin, vol.95, issue.12, pp.3653-61, 2000. ,
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases, Blood. 21 mai, vol.113, issue.21, pp.5064-73, 2009. ,
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer, Blood. 1 juill, vol.90, issue.1, pp.354-71, 1997. ,
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects, J Cutan Pathol, vol.32, issue.10, pp.647-74, 2005. ,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood. 12 mai, vol.117, pp.5019-5051, 2011. ,
Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases, Br J Dermatol. juin, vol.172, issue.6, pp.1547-54, 2015. ,
A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders, Semin Diagn Pathol. janv, vol.34, issue.1, pp.22-35, 2017. ,
Cutaneous CD30-positive T-cell lymphoproliferative disordersclinical and histopathologic features, differential diagnosis, and treatment, Semin Cutan Med Surg. mars, vol.37, issue.1, pp.24-33, 2018. ,
Primary cutaneous CD30(+) lymphoproliferative disorders, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. août, vol.14, issue.8, pp.767-82, 2016. ,
Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant, Arch Dermatol. janv, vol.97, issue.1, pp.23-30, 1968. ,
Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncol Williston Park N, vol.23, pp.1158-64, 2009. ,
Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients, J Am Acad Dermatol. janv, vol.74, issue.1, pp.59-67, 2016. ,
Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas, Am J Surg Pathol. janv, vol.37, issue.1, pp.1-13, 2013. ,
Regional lymphomatoid papulosis: a report of four cases, Br J Dermatol. déc, vol.141, issue.6, pp.1125-1133, 1999. ,
Report of two cases and review of the literature, Dermatol Basel Switz, vol.210, issue.1, pp.53-60, 2005. ,
Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C, Arch Dermatol. avr, vol.140, issue.4, pp.441-448, 2004. ,
Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis, Am J Surg Pathol. août, vol.37, issue.8, pp.1173-81, 2013. ,
The spectrum of CD30+ T cell lymphoproliferative disorders in the skin, Chin Clin Oncol, vol.8, issue.9, 2019. ,
ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma, Blood, vol.118, issue.15, pp.4024-4059, 2011. ,
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.32, pp.3759-65, 2015. ,
Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis, The Oncologist. janv, vol.21, issue.1, pp.76-83, 2016. ,
Systemic and primary cutaneous anaplastic large cell lymphomas, Semin Hematol. juill, vol.40, issue.3, pp.244-56, 2003. ,
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases, Am J Surg Pathol, vol.22, issue.10, pp.1192-202, 1998. ,
CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, J Am Acad Dermatol. déc, vol.49, issue.6, pp.1049-58, 2003. ,
Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma, Arch Dermatol. déc, vol.145, issue.12, pp.1399-404, 2009. ,
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome, Arch Dermatol. juin, vol.145, issue.6, pp.667-74, 2009. ,
Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. mai, vol.10, issue.5, pp.331-340, 2012. ,
Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage, Arch Dermatol, vol.131, issue.11, pp.1281-1289, 1995. ,
Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. août, vol.13, issue.8, pp.2146-53, 2013. ,
Posttransplant CD30+ anaplastic large cell lymphoma with skin and lymph node involvement, Dermatol Basel Switz, vol.207, issue.1, pp.107-117, 2003. ,
The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases, Am J Surg Pathol, vol.23, issue.10, pp.1208-1224, 1999. ,
Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.14, pp.1888-90, 2016. ,
,
, Ann Dermatol Venereol. juill, vol.145, issue.6-7, pp.433-441, 2018.
Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab, JAAD Case Rep. mars, vol.1, issue.2, pp.56-65, 2015. ,
Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate, Mayo Clin Proc. août, vol.76, issue.8, pp.845-853, 2001. ,
Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin, Carcinogenesis. févr, vol.24, issue.2, pp.301-307, 2003. ,
Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas, Am J Pathol. déc, vol.137, issue.6, pp.1317-1339, 1990. ,
Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators, J Invest Dermatol. févr, vol.130, issue.2, pp.563-75, 2010. ,
CCL27-CCR10 interactions regulate T cell-mediated skin inflammation, Nat Med. févr, vol.8, issue.2, pp.157-65, 2002. ,
A skin-selective homing mechanism for human immune surveillance T cells, J Exp Med. 3 mai, vol.199, issue.9, pp.1265-75, 2004. ,
Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL, Br J Dermatol. août, vol.143, issue.2, pp.313-322, 2000. ,
A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma, Blood, vol.94, issue.8, pp.2854-61, 1999. ,
AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells, Am J Pathol. août, vol.163, issue.2, pp.633-674, 2003. ,
Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies, Mod Pathol Off J U S Can Acad Pathol Inc. avr, vol.24, issue.4, pp.596-605, 2011. ,
Unlikely role of Epstein-Barr virus in the pathogenesis of primary cutaneous CD30+ anaplastic large cell lymphoma, Eur J Dermatol EJD. juin, vol.11, issue.3, pp.203-211, 2001. ,
Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea, Int J Dermatol, vol.45, issue.11, pp.1312-1318, 2006. ,
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features, Blood. 1 déc, vol.96, issue.12, pp.3681-95, 2000. ,
Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases, Histopathology. août, vol.55, issue.2, pp.189-96, 2009. ,
Primary cutaneous anaplastic large cell lymphoma with angioinvasive features and cytotoxic phenotype: a rare lymphoma variant within the spectrum of CD30+ lymphoproliferative disorders, Dermatol Basel Switz, vol.227, issue.4, pp.346-52, 2013. ,
Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients, Am J Pathol. déc, vol.135, issue.6, pp.1169-78, 1989. ,
Primary Cutaneous LymphomaAssociated Pseudoepitheliomatous Hyperplasia Masquerading as Squamous Cell Carcinoma in a Young Adult, p.4 ,
Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma, Am J Surg Pathol. avr, vol.19, issue.4, pp.407-423, 1995. ,
The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants, J Cutan Pathol. janv, vol.35, issue.1, pp.46-53, 2008. ,
Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features, Histopathology, vol.39, issue.5, pp.476-81, 2001. ,
Primary cutaneous sarcomatoid anaplastic large-cell lymphoma, Am J Dermatopathol. mai, vol.34, issue.3, pp.301-305, 2012. ,
Primary Cutaneous Sarcomatoid Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma With Linear Distributional Lesions, Am J Dermatopathol, vol.39, issue.11, pp.863-869, 2017. ,
Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia, J Cutan Pathol. juill, vol.31, issue.6, pp.458-61, 2004. ,
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas, Blood. 13 sept, vol.120, issue.11, pp.2280-2289, 2012. ,
No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course, Blood, vol.07, issue.1, pp.141-144, 2016. ,
CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases, Am J Clin Pathol. avr, vol.105, issue.4, pp.440-50, 1996. ,
Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome, Chin Clin Oncol. 19 juill, 2018. ,
Disturbed expression of the Tcell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations, Haematologica, vol.95, issue.10, pp.1697-704, 2010. ,
ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study, Haematologica. janv, vol.98, issue.1, pp.50-56, 2013. ,
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?, Hematol Oncol. déc, vol.27, issue.4, pp.161-70, 2009. ,
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas, Leukemia. mars, vol.23, issue.3, pp.574-80, 2009. ,
The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin, Blood. 15 avr, vol.87, issue.8, pp.3437-3478, 1996. ,
The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t(2;5)(p23;q35) chromosomal translocation, J Cutan Pathol. août, vol.24, issue.7, pp.403-411, 1997. ,
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood. 15 juin, vol.111, issue.12, pp.5496-504, 2008. ,
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity, Mol Cell Biol. déc, vol.18, issue.12, pp.6951-61, 1998. ,
ALKnegative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes, Blood. 28 août, vol.124, issue.9, pp.1473-80, 2014. ,
Primary Cutaneous ALCL With Phosphorylated/Activated Cytoplasmic ALK and Novel Phenotype: EMA/MUC1+, Cutaneous Lymphocyte Antigen Negative, Am J Surg Pathol. sept, vol.32, issue.9, pp.1421-1427, 2008. ,
Non-Mycosis Fungoides Cutaneous T-Cell Lymphomas, Am J Clin Pathol. 1 avr, vol.139, issue.4, pp.491-514, 2013. ,
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, Blood. 11 janv, 2019. ,
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing, Blood. 20 janv, vol.117, issue.3, pp.915-924, 2011. ,
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas, Blood. 1 avr, vol.95, issue.7, pp.2212-2220, 2000. ,
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis, Blood. 15 août, vol.92, issue.4, pp.1150-1159, 1998. ,
Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium, J Am Acad Dermatol. févr, vol.70, issue.2, pp.374-380, 2014. ,
Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases, Blood. 16 févr, vol.119, issue.7, pp.1643-1652, 2012. ,
Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas, Blood. 1 juin, vol.93, issue.11, pp.3637-3679, 1999. ,
CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma, Mod Pathol Off J U S Can Acad Pathol Inc. avr, vol.23, issue.4, pp.547-58, 2010. ,
Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes, J Invest Dermatol. juin, vol.130, issue.6, pp.1707-1725, 2010. ,
Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides, Exp Dermatol. août, vol.21, issue.8, pp.632-636, 2012. ,
IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases, J Invest Dermatol. mars, vol.130, issue.3, pp.816-841, 2010. ,
Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease, Br J Dermatol. mars, vol.172, issue.3, pp.784-792, 2015. ,
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma, Br J Dermatol. août, vol.175, issue.2, pp.325-358, 2016. ,
Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples, J Dermatol Sci, vol.64, issue.2, pp.142-146, 2011. ,
Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin, Cancer Control J Moffitt Cancer Cent. avr, vol.14, issue.2, pp.124-156, 2007. ,
Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality, J Am Acad Dermatol, vol.49, issue.4, pp.620-623, 2003. ,
Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients, Clin Exp Dermatol. juill, vol.34, issue.5, pp.576-81, 2009. ,
Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence, Blood. 18 juin, vol.113, issue.25, pp.6372-81, 2009. ,
Epstein-Barr virus infection, N Engl J Med. 17 août, vol.343, issue.7, pp.481-92, 2000. ,
EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment, Blood. 13 août, vol.126, issue.7, pp.863-72, 2015. ,
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders, Front Oncol, vol.9, p.109, 2019. ,
Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases, Cancer. janv, vol.43, issue.1, pp.360-73, 1979. ,
,
, Rev Med Interne. juin, vol.34, issue.6, pp.349-57, 2013.
EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression, Am J Surg Pathol. mars, vol.34, issue.3, pp.405-422, 2010. ,
Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma, Adv Radiat Oncol. sept, vol.2, issue.3, pp.363-372, 2017. ,
Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group, Int J Radiat Oncol Biol Phys, vol.01, issue.5, pp.1279-85, 2017. ,
Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience, Int J Radiat Oncol Biol Phys, vol.01, issue.5, pp.1454-1463, 2016. ,
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial, Lancet Lond Engl. 05, vol.390, pp.555-66, 2017. ,
Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature, Br J Dermatol, vol.177, issue.6, pp.1503-1512, 2017. ,
Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data, Int J Dermatol. déc, vol.56, issue.12, pp.1400-1405, 2017. ,
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.32, pp.3750-3758, 2015. ,
Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand, Ann N Y Acad Sci. sept, vol.941, pp.59-68, 2001. ,
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells, Blood. oct, vol.66, issue.4, pp.848-58, 1985. ,
CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF, Cell. 2 juill, vol.73, issue.7, pp.1349-60, 1993. ,
Antibody-Based Therapies for Cutaneous T-Cell Lymphoma, Am J Clin Dermatol, issue.15, 2018. ,
,
CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis, Int J Oncol [Internet]. 1 févr, 2003. ,
,
Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin, J Cutan Pathol. déc, vol.35, issue.12, pp.1100-1107, 2008. ,
CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators, J Cutan Pathol. févr, vol.33, issue.1, pp.58-70, 2006. ,
, Annexe II : Le cluster de différenciation CD30+
, que l'équipe de Stein a découvert l'antigène Ki-1 ou CD30 comme un récepteur cytokinique impliqué dans la prolifération tumorale des cellules CD30+, p.105, 1982.
aussi appelé TNFRSF8 ou antigène Ki-1, est un marqueur d'activation des lymphocytes T ,
, Ce récepteur transmembranaire est une glycoprotéine de 120kDa appartenant à la superfamille des récepteurs au Tumor Necrosis Factor (TNF) (107)
, On sait actuellement qu'il est impliqué dans l'activation de l'apoptose, la régulation des lymphocytes T CD4+ (108) et qu'il limite la prolifération des lymphocytes T CD8+ autoréactifs avec un rôle
, On le retrouve dans d'autres lymphomes primitivement cutanés (PLy et les TMF) et systémiques (les cellules de Reed Sternberg des lymphomes de Hodgkin expriment en plus le CD15
, Hormis les lymphomes, il est exprimé par les cellules des carcinomes embryonnaires, ce qui permet leur distinction avec les seminomes qui ne l
, le retrouve dans des pathologies plus bénignes comme les piqures d'arthropodes, les nodules d'Orf, les nodules scabieux, les leishmanioses, les syphilis, les lésions cutanées herpétiques HSV et VZV? (110, vol.111
, Cet antigène CD30+ est actuellement la cible de traitement ciblé comme le Brentuximab Vedotin (8), p.66
, Stadification TNM Réponse après troisième ligne : Réponse complète (RC) : Réponse partielle (RP) : Progression ou stable (P) : Quatrième ligne ? : Si oui : Car non réponse (RP ou P) à la précédente ligne : oui non Car rechute après rémission complète : oui non Si oui : Date de rechute :???????
, Rechute cutanée : oui / non. Si oui, localisation : ?????. Rechute ganglionnaire : oui / non. Si oui, localisation : ????
, Réponse partielle (RP) : Progression ou stable
,
, En présence des Maîtres de cette FACULTE et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'Honneur et de la Probité dans l
, Je donnerai mes soins gratuits à l'indigent et je n'exigerai jamais un salaire au-dessus de mon travail
, Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les moeurs ni à favoriser le crime
, Respectueux et reconnaissant envers mes MAÎTRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères
, Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'OPPROBRE et méprisé de mes confrères si j'y manque